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Summary
 
Gram-negative bacterial lipopolysaccharide (LPS) stimulates phagocytic leukocytes by interact-
ing with the cell surface protein CD14. Cellular responses to LPS are markedly potentiated by
the LPS-binding protein (LBP), a lipid-transfer protein that binds LPS aggregates and transfers
LPS monomers to CD14. LBP also transfers LPS to lipoproteins, thereby promoting the neu-
tralization of LPS. LBP present in normal plasma has been shown to enhance the LPS respon-
siveness of cells in vitro. The role of LBP in promoting LPS responsiveness in vivo was tested
in LBP-deficient mice produced by gene targeting in embryonic stem cells. Whole blood from
LBP-deficient animals was 1,000-fold less responsive to LPS as assessed by the release of tumor
necrosis factor (TNF)-
 
a
 
. Blood from gene-targeted mice was devoid of immunoreactive LBP,
essentially incapable of transferring LPS to CD14 in vitro, and failed to support cellular re-
sponses to LPS. These activities were restored by the addition of exogenous recombinant mu-
rine LBP to the plasma. Despite these striking in vitro findings, no significant differences in
TNF-
 
a
 
 levels were observed in plasma from wild-type and LBP-deficient mice injected with
LPS. These data suggest the presence of an LBP-independent mechanism for responding to
LPS. These LBP knockout mice may provide a tool for discovering the nature of the presumed
second mechanism for transferring LPS to responsive cells.
 
L
 
ipopolysaccharide (LPS) is the major lipid component
of the outer membrane of Gram-negative bacteria (1)
and the major initiator of innate immune responses to bac-
terial infection. In the sepsis syndrome, exaggerated re-
sponses to LPS may have life-threatening side effects such
as multiorgan failure and sepsis-related shock.
The earliest cell-mediated events after endotoxin release
appear to involve the transfer of LPS to a glycosyl phos-
phatidyl inositol (GPI)-linked protein known as CD14.
Evidence supporting a central role for CD14 in LPS-medi-
ated responses includes the following: (
 
a
 
) LPS binds stoichi-
ometrically to CD14 (2), (
 
b
 
) monoclonal antibodies to
CD14 inhibit the ability of LPS to stimulate phagocytes (3),
(
 
c
 
) a soluble fragment of CD14 (sCD14) is present in blood
(4) and facilitates the activation of cells that do not express
membrane CD14 (5), (
 
d
 
) transfection of CD14 into CD14-
negative cell lines enhances the responsiveness of these cells
to LPS by 
 
.
 
1,000-fold (6, 7). The physiological relevance
of these observations was underscored by the finding that
CD14-gene disrupted mice are 10,000-fold less sensitive to
LPS than matched littermates (8).
LPS is a sparingly soluble amphiphile that forms aggre-
gates in aqueous medium. As a consequence, spontaneous
diffusion of LPS monomers from aggregates to the binding
site on CD14 occurs at a very slow rate (2). A plasma pro-
tein known as lipopolysaccharide-binding protein (LBP;
reference 9), however, accelerates binding of LPS mono-
mers to CD14 (2) and thereby enhances the sensitivity of
cells to LPS (10). LBP acts as a lipid transfer protein, cata-
lytically transferring LPS monomers from aggregates to
CD14 (2, 11). This function is in keeping with its sequence
homology to the lipid transfer proteins phospholipid trans-
fer protein and cholesterol ester transfer protein. Additional
studies have shown that LBP copurifies with HDL particles
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(12) and also acts to transfer LPS into complexes of high
density lipoprotein (HDL) (13) where LPS is functionally
neutralized (14). Thus, LBP may serve both to enhance and
to neutralize the biological activity of LPS.
We sought to clarify the role of LBP in vivo by deleting
the gene from mice. We report that whole blood from the
LBP
 
2
 
/
 
2
 
 knockout (KO) animal has no LBP activity, and
the response to LPS as an activator of cytokine production
in vitro was shifted by 
 
z
 
1,000-fold. Much to our surprise,
this remarkable in vitro phenotype was not matched in
vivo. Although small deficiencies in response to LPS were
observed at the lowest doses of injected LPS, overall, no
significant difference in response was observed. Although
several potential explanations for this apparent dichotomy
exist, we propose that the role of LBP in enhancing LPS
signaling is limited to the bloodstream and may contribute
little to morbidity and mortality associated with endotox-
emia. Furthermore, we propose that a novel protein with
LBP-like capabilities may exist in LPS-responsive tissues.
 
Materials and Methods
 
Reagents.
 
Unless otherwise stated, all materials were pur-
chased from Sigma Chemical Co. (St. Louis, MO). 
 
Escherichia coli
 
LPS (0111:B4) was purchased from List Biologicals (Campbell, CA).
 
Construction of the LBP Knockout Vector.
 
Screening of a mu-
rine 129/SVJ genomic library in the P1 cloning vector was per-
formed by Genome Systems, Inc. (St. Louis, MO). A genomic
clone was identified using primer pairs to generate PCR products
corresponding to portions of the murine LBP 5
 
9
 
 untranslated region
(UTR) (5
 
9
 
-CGGGGCCTCTCTTTCCCGC-3
 
9
 
, 5
 
9
 
-CCTGGA-
TGCTCCGTGGGGG-3
 
9
 
) and 3
 
9
 
 UTR (5
 
9
 
-GGGTCTCAG-
TGGCCACAGC-3
 
9
 
, 5
 
9
 
-CAGGTCTCCCACCCAGTGTTG-
3
 
9
 
). Exons 1–3 were sequenced and found to be identical to the
murine LBP cDNA sequence (These sequence data are available
from EMBL/GenBank/DDBJ under accession number X99347).
A 8.4-kb NheI–NdeI subclone was used to construct the target-
ing vector. A 1.4-kb SpeI fragment was replaced with the neo-
mycin phosphotransferase gene (neo) in the opposite transcrip-
tional orientation from the LBP gene. Replacement of LBP
sequences with the neo cassette deleted a portion of the 5
 
9
 
 UTR,
the start codon and subsequent 40 amino acids, and introduced a
new EcoRV restriction site. A map of the 5
 
9
 
 portion of the LBP
gene and the targeting vector is shown in Fig. 1.
 
Generation of Mutant Embryonic Stem Cell Line.
 
The vector (15
 
m
 
g) was linearized with XhoI and transfected into the R1 embry-
onic stem (ES) cells (15). ES cells were transferred onto irradiated
neo
 
resistant
 
 primary embryonic fibroblasts and stable integrants were
selected using G418 (350 
 
m
 
g/ml, GIBCO BRL, Gaithersburg,
MD). To identify clones that underwent homologous recombina-
tion, ES cell DNA was digested with EcoRV, and analyzed by
Southern blot hybridization using a PCR-generated probe de-
rived from sequence external to the targeting vector (Fig. 1;
5
 
9
 
-CGGTTCTCAAATATTTGCGTCACCCC-3
 
9
 
, 5
 
9
 
-CTTTG-
GGCTTCCATGTCCCAGGAACC-3
 
9
 
).
 
Generation of Germline Chimeras and Homozygous Mutant Mice.
 
An ES cell clone that underwent homologous recombination was
expanded and injected into C57BL/6J blastocysts. The resulting
chimeric animals were backcrossed to C57BL/6J (Jackson Labo-
ratories, Bar Harbor, ME) mice. Germline transmission was iden-
tified by Southern blot analysis of tail DNA. Hemizygous animals
were crossed and homozygous offspring were identified by
Southern blot as shown in Fig. 2.
 
Reverse Transcriptase PCR of LBP Messenger RNA from Mouse
Liver.
 
To design primer pairs, a genomic fragment containing
the second and third exons of LBP was sequenced. Similarly, a
downstream genomic fragment containing a portion of the 3
 
9
 
-
UTR was sequenced at the 3
 
9
 
 end. The presence of LBP messen-
ger RNA (mRNA) was detected using a 5
 
9
 
 primer within the
sequence in exon 3 (5
 
9
 
-GGCTCTGCAGAGAGAGCTGTA-
CAA-3
 
9
 
) and a 3
 
9
 
 primer from the penultimate exon (5
 
9
 
-TAG-
TTAAGGAATGCCTGGAACAGG-3
 
9
 
). Using these primers,
the predicted product from mRNA is 1.1 kb; the predicted prod-
uct from the amplification of genomic DNA is 
 
>
 
10 kb. glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) was amplified as a
control (5
 
9
 
 primer: GTCATCATCTCCGCCCCTTCTGC; 3
 
9
 
primer: GATGCCTGCTTCACCACCTTCTTG).
Livers and kidneys from hemizygous or homozygous age- and
gender-matched mice were removed under anesthesia (Metofane;
Henry Schein, Port Washington, NY). RNA was extracted using
Figure 1. Targeting vector. The genomic
organization of murine LBP is shown and
compared with the targeting vector. The
mutant construct removes a portion of the
59 UTR, the translational start site, the next
40 amino acids, and the first splice donor site. 
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RNazol (Tel-test, Friendswood, TX). Poly-A mRNA was puri-
fied using the PolyATtract mRNA Isolation System III kit
(Promega, Madison, WI), and 10 ng of mRNA was reverse tran-
scribed with Superscript II (GIBCO BRL). One tenth of the total
reverse-transcribed product was used as template per PCR reac-
tion. Each reaction contained PCR primers (500 nM), MgCl
 
2
 
 (2
mM), deoxy nucleotides triphosphates (dNTPs) (200 
 
m
 
M), and 1
unit Taq polymerase in a total volume of 25 
 
m
 
l. PCR conditions
were 94
 
8
 
C for 1 min, 60
 
8
 
C for 45 s, and 1.5 min at 72
 
8
 
C for 35
cycles. Amplified fragments were resolved on a 3% agarose gel.
 
LBP/LPS Binding Assay (16).
 
ELISA plates (MaxiSorp; Nunc,
Wiesbaden, Germany) were coated with LPS, washed, and dried.
Plates were blocked with incubation buffer (50 mM Hepes, 150
mM NaCl, pH 7.4) containing 10 mg/ml BSA. Mouse plasma
was serially diluted in incubation buffer plus BSA, added to each
well, and incubated for 2 h at 37
 
8
 
C. After washing, 100 
 
m
 
l/well
of a rabbit polyclonal antirecombinant murine LBP antibody (5
 
m
 
g/ml) was added and incubated for 1 h at 37
 
8
 
C. Wells were de-
veloped using an anti–rabbit Ig horseradish peroxidase conjugate
(BioGenes, Berlin, Germany) with 
 
o
 
-phenylenediamine dihydro-
chloride as substrate.
 
Measurement of LPS Transfer Activity.
 
LPS transfer assays with
boron dipyrromethane (BODIPY)-labeled LPS were as described
(17) except that the assay was adapted to a 96-well format, and
fluorescence was recorded with a Cytofluor II fluorescence plate
reader (PerSeptive Biosystems, Framingham, MA). All reagents
were diluted in Dulbecco’s PBS to a total volume of 200 
 
m
 
l/well
using Immulon-1 plates (Dynatech Laboratories, Inc., Chantilly,
VA). All readings were blanked against Dulbecco’s PBS.
 
LPS Stimulation of TNF-
 
a
 
 Release.
 
KO mice and hemizygous
littermates were matched for gender and weight. Blood was
drawn in heparinized capillary tubes via the retroorbital plexus
under anesthesia. Whole blood (40 
 
m
 
l/tube) was mixed with an
equal volume of LPS suspended as a dispersion in PBS and 4 U/
ml heparin and incubated for 4 h at 37
 
8
 
C. TNF-
 
a
 
 concentrations
in the supernatants were measured by ELISA (Genzyme, Cam-
bridge, MA).
In some experiments, washed peripheral blood cells containing
a mixed population of leukocytes were also used as a source of
LPS-inducible cytokines. Heparinized whole blood was subjected
to centrifugation at 400 
 
g
 
, and the cellular pellet was washed
twice and resuspended in the original volume of PBS. A 40-
 
m
 
l
portion of these cells was then mixed with pooled plasma from
LBP
 
1
 
/
 
2
 
 or LBP
 
2
 
/
 
2
 
 mice and incubated with LPS (1 ng/ml) for 4 h
at 37
 
8
 
C. TNF-
 
a
 
 concentrations in the supernatants were then
measured by ELISA.
 
In Vivo Stimulation of TNF-
 
a
 
 Production after Intravenous Injection
of LPS.
 
LPS was suspended in 0.2 ml of sterile nonpyrogenic
saline (Abbott Laboratories, Chicago, IL) at the stated concentra-
tion. Hemizygous (LBP
 
1
 
/
 
2
 
) and homozygous (LBP
 
2
 
/
 
2
 
) mice (3/
 
group) were anesthetized and injected intravenously via the ret-
roorbital plexus. Plasma TNF-
 
a
 
 levels were measured by ELISA
from blood collected 90 min after injection.
 
Results
 
A Mutant LBP Transcript Is Expressed at Low Levels in
LBP
 
2
 
/
 
2
 
 Mice.
 
Initial restriction mapping of the murine
LBP gene demonstrated that it is at least 14 kb in length.
Since the gene was too large to delete in its entirety, we
constructed a vector to delete the first exon, including the
translational start site, and part of the first intron. PCR
primers derived from the deleted region of the 5
 
9
 
 UTR to
the 3
 
9
 
 UTR amplified the predicted products from RNA
derived from wild-type mice but not KO mice, thus con-
firming the deletion (data not shown). To determine if the
remaining portion of the gene was transcribed in KO ani-
mals, RNA was prepared and subjected to reverse tran-
scriptase PCR analysis using primers that were not in the
region of the gene deletion. Liver mRNA from LBP
 
2
 
/
 
2
 
mice expressed only a small fraction of LBP transcript in
comparison to wild-type mice and no LBP mRNA was
detected in kidneys from 
 
2
 
/2 mice (Fig. 3). These data
confirmed that the KO mouse expresses very low levels of
mutant LBP transcript. Even if the mutant mRNA were
translated successfully, the resultant protein would be trun-
cated and probably expressed at very low levels.
Plasma from LBP2/2 Mice Appears to Lack Functional LBP.
To determine if blood contained a functional mutant LBP
molecule, we analyzed plasma from KO mice for LBP-like
activity. The ability of LBP to bind LPS and to form a sta-
ble complex has been well described (9, 16). We incubated
plasma from the KO mouse with LPS-coated plastic,
washed the wells with buffer, and developed the plate with
a polyclonal antiserum against murine LBP. Although
hemizygous mice expressed wild-type levels of LBP, their
homozygous gene-targeted littermates had no detectable
LBP (Fig. 4 a).
LBP not only binds LPS aggregates but also transfers LPS
monomers from LPS aggregates to CD14 (2). This prop-
erty of LBP can be studied in a fluorescent assay, using BO-
DIPY-labeled LPS, in which fluorescence is quenched in
its aggregate state (17). As labeled LPS monomers exit from
LPS aggregates and bind to CD14, an increased fluorescent
signal can be observed. This process is greatly accelerated
by the presence of substoichiometric quantities of LBP (2,
17). Thus, it was possible to ask if the KO plasma contained
functional LBP. Although the plasma from the hemizygous
Figure 2. Southern blotting analysis of DNA from mutant LBP2/2,
hemizygous LBP1/2, and homozygous LBP1/1 F1 littermates. Southern
blots of tail-tip DNA of mice from the first heterozygote/heterozygote
crossing are shown. The mutant allele is z6 kb and the wild-type allele is
11 kb.
Figure 3. Reverse transcriptase PCR of LBP
mRNA from hemizygous mice and homozy-
gous LBP2/2 littermates. RNA was extracted
from F4 mice, and analyzed by reverse tran-
scriptase PCR. Intron spanning primers were
used; the DNA product resulting from the re-
verse transcription and amplification of LBP mRNA was 1.1 kb, whereas
contaminating genomic DNA had a predicted size of .10 kb. Shown is
one of four representative experiments.2054 LBP Knockout Mice Have Reduced Ex Vivo Cytokine Response to LPS
mice rapidly transferred LPS to soluble CD14, plasma from
the KO mice was virtually inactive (Fig. 4 b). Taken to-
gether, the experiments demonstrated in Fig. 4 a and b sug-
gest that mutant mice either fail to translate their mutant
transcript into secreted protein, or that the resulting protein
produced by the KO mice fails to properly bind or transfer
LPS to CD14.
Whole Blood from the LBP KO Mice Failed to Produce TNF-a
in Response to Low Concentrations of LPS. We measured the
ability of LPS to induce TNF-a secretion in whole blood
ex vivo from the LBP2/2 animals and their hemizygous lit-
termates. Careful dose response studies of the KO animal
revealed that the absence of functional LBP shifted the
dose-response relationship of LPS by at least 1,000-fold
(Fig. 5). The addition of recombinant LBP to whole blood
from the LBP2/2 mouse shifted the curve to closely resem-
ble that of the hemizygous mouse (Fig. 5). Thus, blood
from mice with the targeted deletion of the LBP gene was
markedly hyporesponsive to LPS, presumably as a result of
the inability of LPS to rapidly associate with CD14.
Figure 4. Plasma from the knock-out mice does not contain functional LBP. (a) LPS-coated plastic was incubated with plasma from wild-type LBP1/1, hemi-
zygous LBP1/2, and homozygous LBP2/2 mice. LPS-bound LBP was detected by incubating washed wells with polyclonal anti-LBP serum as described
in Materials and Methods. No detectable LBP remained bound to the plastic in plasma from the KO animals. (b) Plasma from LBP1/2 animals was com-
pared to plasma from homozygous LBP2/2 animals for its ability to mediate transfer of LPS to sCD14. B-LPS plus LBP1/2 plasma plus sCD14 (d), B-LPS
plus LBP2/2 plasma plus sCD14 (m), B-LPS plus LBP1/2 plasma (s), B-LPS plus LBP2/2 plasma (n), B-LPS alone (h). The KO plasma had virtually
no ability to transfer LPS to sCD14. Addition of recombinant LBP to LBP2/2 plasma restored activity (not shown). Results are representative of four sepa-
rate experiments.
Figure 5. Ex vivo cytokine responses by blood from LBP2/2 mice was
markedly hyporesponsive to exogenously added LPS. Whole blood was
obtained from 1/2 and 2/2 mice, pooled, and assessed for LPS respon-
siveness as described in Materials and Methods. Recombinant LBP was
added to achieve a final concentration of 2 mg/ml. Each data point is ex-
pressed as the mean 1/2 range of two separate experimental wells (each
of which was measured in duplicate). Shown is one of four similar exper-
iments.
Figure 6. In vivo cytokine response to LPS injection in homozygous
2/2 KO and hemizygous 1/2 mice are nearly identical. Age- and sex-
matched mice were injected intravenously under anesthesia with 200 ml
of LPS at the indicated concentrations via the retroorbital plexus. After 90
min, mice were reanesthetized and phlebotomized using heparinized cap-
illary tubes. Each of three mice was assessed separately per condition.
Plasma TNF-a was determined by ELISA. Shown is a representative ex-
periment from six similar experiments (three intravenous and three intra-
peritoneal injections).2055 Wurfel et al. Brief Definitive Report
Additional studies showed that responses of LBP2/2 cells
could be restored with plasma from LBP1/2 animals. Blood
cells were washed out of whole blood from LBP2/2 ani-
mals and their hemizygous littermates and were resus-
pended in PBS containing pooled sera from the LBP1/2 or
LBP2/2 littermates. When cells from either mouse were
stimulated with LPS (1 ng/ml) in plasma from hemizy-
gotes, they responded to LPS by releasing TNF-a. In con-
trast, cells were unresponsive to LPS when incubated with
LPS in the presence of LBP2/2 plasma, regardless of
whether they were derived from hemizygous LBP1/2 or
homozygous KO animals (data not shown). 
Injection of LPS into LBP KO Animals Results in Normal
Expression of TNF-a. We predicted that the LBP KO
mouse would be markedly hyporesponsive to the systemic
administration of LPS. KO mice, representing F2 through
F4 generations, were matched for age and sex and injected
intravenously with graded concentrations of LPS. Surpris-
ingly, the KO mice responded nearly identically to the
hemizygous littermates over a wide range of doses (Fig. 6).
Although at the lowest dose of LPS, a trend towards less re-
sponse may have been seen in the KO animals, these doses
were far lower than the dose of LPS needed to kill an ani-
mal (or even produce visible signs of morbidity). This was
true regardless of the route of administration, as intraperito-
neal injections of endotoxin produced similar results (data
not shown). These results contrast dramatically with the
differences observed ex vivo in which blood from the mu-
tant LBP2/2 mice was z1,000-fold less responsive than
blood from hemizygous LBP1/2 littermates.
Discussion
Gene targeting and homologous recombination were
used to delete the LBP gene from mice. Plasma from the
mice appeared devoid of LBP since LPS-coated plastic
treated with this plasma did not accumulate immunoreac-
tive LBP and plasma derived from the KO animal demon-
strated a strikingly reduced ability to transfer LPS to
sCD14. LBP is thought to promote responses to LPS by
catalyzing the transfer of LPS to CD14. Consistent with
this notion, we observed that whole blood from LBP2/2
animals showed dramatically reduced ability to produce
TNF-a, requiring nearly 1,000-fold more LPS for a half-
maximal response than blood from LBP1/2 animals. The
LBP necessary for cellular responses in these studies was
clearly due to differences between the two sources of plasma
since adding LBP1/2 plasma to LBP2/2 cells fully restored
sensitivity to LPS, and hyporesponsiveness was reversed by
the addition of recombinant murine LBP. These experimental
findings confirm the important role of LBP in mediating
sensitive responses of monocytes and macrophages to LPS.
Studies on the responses of living mice yielded a surpris-
ingly different result. The production of TNF-a in re-
sponse to LPS was nearly indistinguishable for LBP2/2 and
LBP1/2 mice, especially at doses sufficient to result in shock
and death. This result was surprising in light of the report
that a CD142/2 mouse showed strongly depressed re-
sponses to a similar LPS challenge (8). It thus appears that
the LBP2/2 mouse reported here may respond to LPS in a
CD14-dependent but LBP-independent fashion. One ten-
tative conclusion that might be drawn from these data is
that blood is not the compartment that is primarily respon-
sible for cytokinemia resulting from endotoxemia. Even so,
an additional mechanism is needed to explain how tissue
phagocytes and other TNF-a–producing cells can respond
to LPS independently of LBP. We envision two potential
explanations for these results.
Low levels of a functional, truncated LBP might be pro-
duced in the liver but might fail to be expressed in blood
due to the introduced mutation. We do not favor this hy-
pothesis. Previous studies have shown that the NH2-termi-
nal half of LBP is responsible for its LPS binding activity
and the COOH-terminal half contains the activity respon-
sible for transferring LPS to CD14 (18, 19). Although it is
possible that a truncated LBP gene product could be gener-
ated by translation of an LBP transcript at an internal me-
thionine codon, the first potential initiation codon within
the LBP locus (methionine 146) is beyond the putative
LPS-binding domain, and the resulting protein would not
possess LPS-binding activity. Moreover, the mutant LBP
partial transcript was expressed at very low levels in the liv-
ers of the KO mice (Fig. 3), and any resulting protein
would be expressed at vanishingly low levels.
A more attractive explanation for the LPS responsiveness
of the LBP KO mice is that a protein distinct from LBP
may transfer LPS to CD14 within tissues. In this regard,
Acton et al. (20) have recently described a membrane pro-
tein (the class B scavenger receptor, SR-BI) that transfers
lipids from high density lipoproteins to the plasma mem-
branes of hepatocytes, and Vassellon et al. have described a
protease-sensitive activity on the surface of leukocytes that
appears to transfer LPS from CD14 to the membranes (21).
These studies offer precedence for cell-associated lipid transfer
proteins that might exist on endothelial cells or other ele-
ments in tissues.
We wish to stress that our results do not rule out a con-
tribution of LBP to LPS responsiveness under all circum-
stances in vivo. The proteins contributing to a response
might vary with the type and physical state of the LPS,
with the route of administration, and with the physiologi-
cal state of the animals (resting or acute phase). In fact, pre-
liminary studies suggest that LBP2/2 animals may show de-
pressed responses to LPS under some dosing regimens (not
shown). This observation is in keeping with the ability of
LBP to enable responses in whole blood and the ability of
anti-LBP to block responses of animals to LPS (22). Re-
dundant or overlapping mechanisms are commonly ob-
served in vital physiological functions and should be ex-
pected in host response to Gram-negative infection. The
most important conclusion from our work is that animals
do possess machinery that acts in parallel or in addition to
LBP to initiate cellular responses to LPS. The availability of
the LBP2/2 animal makes it possible to seek the nature of
this additional machinery.2056 LBP Knockout Mice Have Reduced Ex Vivo Cytokine Response to LPS
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